SCYNEXIS Announces Presentations Highlighting the Potent Antifungal Activity of its Second-Generation Fungerp, SCY-247 Against Drug-Resistant Fungi, at the Inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI)
MWN-AI** Summary
SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company focused on developing innovative treatments for drug-resistant infections, has announced its participation in the inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI) from January 28-30, 2026, in Las Vegas. The company will present findings on its second-generation fungerp drug candidate, SCY-247, which demonstrates significant antifungal activity against drug-resistant fungi. David Angulo, M.D., President and CEO of SCYNEXIS, expressed the company's enthusiasm about sharing SCY-247’s promising in vitro and in vivo antifungal capabilities, alongside its favorable safety profile, at this pivotal conference aimed at combating antimicrobial resistance.
An oral presentation detailing SCY-247’s efficacy against resistant fungi is scheduled for January 29 during the Plenary session, which will focus on early clinical developments of new antimicrobial agents. Additionally, this information will be showcased in a Poster session on January 30. Details of both the presentation and poster will be made available on the company’s website following the conference.
IMARI, co-organized by the American Society for Microbiology and the Infectious Diseases Society of America, gathers researchers, clinicians, and stakeholders to address the rising threat of antimicrobial resistance, a critical concern for global health.
SCYNEXIS’s portfolio also includes Ibrexafungerp, which has received FDA approval for treating vulvovaginal candidiasis and is seen as a groundbreaking member of its novel fungerp class. SCY-247 is currently in clinical development and has received both Qualified Infectious Disease Product (QIDP) and Fast Track designations from the FDA. While SCYNEXIS is optimistic about the potential of SCY-247, the company cautions that actual outcomes may differ due to various risks associated with drug development.
MWN-AI** Analysis
SCYNEXIS, Inc. (NASDAQ: SCYX) recently announced its participation in the inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI), spotlighting its second-generation antifungal candidate, SCY-247. Given the pressing challenge of drug-resistant fungal infections, the recent presentations may play a pivotal role in the company's strategy and market positioning.
SCY-247 has demonstrated significant antifungal activity against drug-resistant fungi in both in vitro and in vivo studies. The presentations at IMARI, particularly highlighting its favorable safety profile and pharmacokinetics, could attract attention from investors and healthcare professionals alike. This interest is further amplified by the growing global concern over antimicrobial resistance, making SCY-247 a potentially essential therapeutic option.
The drug’s Fast Track and Qualified Infectious Disease Product (QIDP) designations by the FDA underscore its potential importance and could expedite its development trajectory. These designations not only enhance SCYNEXIS' credibility in the fast-evolving biotech landscape but also provide a strategic advantage in securing funding and partnerships.
From an investment perspective, SCYNEXIS presents a compelling opportunity amid a backdrop of increasing urgency for innovative antifungal treatments. However, potential investors should be cautious and remain vigilant regarding the risks outlined in the company's filings, including regulatory hurdles and development costs.
Given the dual burdens of rising drug resistance and the urgent public health needs for effective antifungal therapies, SCYNEXIS is positioned to capitalize on market demand. Future developments, especially following the IMARI presentations, should be monitored closely as advancements could lead to significant shifts in market valuation and investor sentiment. Therefore, maintaining a diversified portfolio while considering a stake in SCYNEXIS may be a prudent approach for risk-aware investors aiming to tap into the burgeoning biotech sector focused on infectious diseases.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
JERSEY CITY, N.J., Jan. 28, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced upcoming presentations highlighting data on the Company’s second-generation fungerp drug candidate, SCY-247, at the inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI), which is taking place from January 28 to 30, 2026, in Las Vegas, Nevada.
“We are pleased to participate in this important inaugural multidisciplinary meeting focused on addressing the significant threat of antimicrobial resistance,” said David Angulo, M.D., President and Chief Executive Officer of SCYNEXIS. “The potent in vitro and in vivo antifungal activity of our second-generation fungerp, SCY-247, together with the favorable safety profile and pharmacokinetics observed in clinical investigations to date, position this novel agent as a potentially critical weapon in the fight against deadly fungal infections, including those resistant to existing antifungal therapies. We look forward to sharing our development progress with the scientific community at IMARI, an especially timely conference given the growing recognition of the serious impact to human health posed by antifungal resistance.”
An oral presentation of SCY-247 highlighting its antifungal activity against resistant fungi, will be included in the Plenary session “New Antimicrobial Agents in The Pipeline: Early Clinical Development” on January 29 from 9-10:30am and will also be displayed in the Poster session on January 30th. The presentation and poster will be posted in the Publications and Presentations section of the Company’s website after the meeting.
IMARI is a joint conference organized by the American Society for Microbiology (ASM) and the Infectious Diseases Society of America (IDSA) that brings together researchers, clinicians, industry leaders and policymakers to address one of the greatest challenges in modern medicine: antimicrobial resistance.
About SCYNEXIS
SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant. SCYNEXIS is developing the company’s proprietary antifungal platform “fungerps.” Ibrexafungerp, the first representative of this novel class, has been licensed to GSK. The U.S. Food and Drug Administration (FDA) has approved BREXAFEMME® (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC) and for reduction in the incidence of recurrent VVC. The second generation fungerp SCY-247 is currently in clinical stages of development and has received QIDP and Fast Track designation from the FDA. Additional antifungal assets from this novel class are currently in pre-clinical and discovery phases. For more information, visit www.scynexis.com.
Forward-Looking Statements
Statements contained in this press release regarding expected future events or results are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements regarding: The characteristics of SCY-247 and its potential to be a key contributor in the fight against deadly fungal infections, including those resistant to existing antifungal therapies. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks inherent in regulatory and other costs in developing products. These and other risks are described more fully in SCYNEXIS' filings with the Securities and Exchange Commission, including without limitation, its most recent Annual Report on Form 10-K filed on March 12, 2025, including under the caption "Risk Factors." All forward-looking statements contained in this press release speak only as of the date on which they were made. SCYNEXIS undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
CONTACT:
Investor Relations
Irina Koffler
LifeSci Advisors
Tel: 917-734-7387
ikoffler@lifesciadvisors.com
FAQ**
How does SCYNEXIS Inc. SCYX plan to leverage its second-generation fungerp drug candidate, SCY-247, in addressing the escalating issue of antifungal resistance as highlighted at the IMARI conference?
What specific data on SCY-247 will SCYNEXIS Inc. SCYX present at the IMARI conference regarding its antifungal efficacy against resistant strains?
Considering recent FDA designations, what are the anticipated milestones for SCYNEXIS Inc. SCYX regarding the clinical development of SCY-247 in the next 12 months?
How does SCYNEXIS Inc. SCYX intend to position itself within the biopharmaceutical landscape in light of the urgency surrounding antimicrobial resistance discussed at IMARI?
**MWN-AI FAQ is based on asking OpenAI questions about SCYNEXIS Inc. (NASDAQ: SCYX).
NASDAQ: SCYX
SCYX Trading
0.92% G/L:
$0.7811 Last:
77,937 Volume:
$0.82 Open:
